Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) was the target of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 14,400,000 shares, a growth of 35.8% from the November 15th total of 10,600,000 shares. Based on an average daily volume of 1,480,000 shares, the short-interest ratio is currently 9.7 days.

Syndax Pharmaceuticals stock traded up $0.46 during midday trading on Friday, reaching $13.93. The stock had a trading volume of 3,875,184 shares, compared to its average volume of 2,072,802. The firm has a market capitalization of $1.19 billion, a PE ratio of -3.84 and a beta of 0.86. Syndax Pharmaceuticals has a 12 month low of $13.26 and a 12 month high of $25.34. The firm's 50-day moving average price is $17.81 and its 200 day moving average price is $19.46.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same period last year, the business posted ($0.73) earnings per share. Equities research analysts expect that Syndax Pharmaceuticals will post -2.39 EPS for the current year.

Several analysts have recently commented on the company. Stifel Nicolaus raised their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a "buy" rating in a report on Monday, October 14th. Citigroup raised their price objective on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday, November 19th. The Goldman Sachs Group upped their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. HC Wainwright reissued a "buy" rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 10th. Finally, UBS Group initiated coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They issued a "buy" rating and a $37.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $37.64.

View Our Latest Research Report on Syndax Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Syndax Pharmaceuticals in the second quarter worth about $27,000. Values First Advisors Inc. bought a new position in Syndax Pharmaceuticals in the 3rd quarter valued at $30,000. nVerses Capital LLC purchased a new position in shares of Syndax Pharmaceuticals during the 2nd quarter valued at $33,000. Quantbot Technologies LP bought a new position in shares of Syndax Pharmaceuticals in the third quarter worth $49,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Syndax Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock worth $58,000 after purchasing an additional 541 shares during the period.

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Syndax Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.

While Syndax Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.